Accepted for/Published in: JMIR Bioinformatics and Biotechnology
Date Submitted: Sep 30, 2021
Date Accepted: Apr 27, 2022
Identification of a novel c.3080delC JAG1 gene mutation associated with Alagille syndrome by whole exome sequencing
ABSTRACT
Background:
Background:
Alagille syndrome is an autosomal dominant disorder associated with variable clinical phenotypic features including cholestasis, congenital heart defects, vertebral defects and dysmorphic facies.
Objective:
Objectives: Whole-exome sequencing (WES) has become technically feasible due to the recent advances in next-generation sequencing technologies, therefore offering new possibilities for mutations/genes identification.
Methods:
Methods:
Next-generation sequencing (NGS) - Whole-exome sequencing was used to identify pathogenic variants of the proband. In this paper, we have uncovered a novel JAG1 mutation associated with Alagille syndrome in a 5 years old girl presented with conjugated hyperbilirubinemia and infantile cholestasis.
Results:
Results:
The exome sequencing analysis revealed the presence of a novel JAG1 heterozygous c.3080delC variant in exon 25. The detected variant introduce a stop codon (p.P1027RfsTer9) in the gene sequence, encoding a truncated protein. Our exome observations were confirmed through Sanger sequencing as well.
Conclusions:
Conclusions:
Here, we report a case of a patient with conjugated hyperbilirubinemia and infantile cholestasis, with emphasis on its association with the detection of novel JAG1 variant thereby, establishing the genetic diagnosis of the Alagille syndrome.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.